TNGX
HealthcareTango Therapeutics, Inc.
$8.91
$-0.02 (-0.22%)
Jan 5, 2026
Price History (1Y)
Analysis
Tango Therapeutics, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $1.20B and 155 employees. The company's revenue reached $66.50M over the trailing twelve months. The financial health of Tango Therapeutics is characterized by significant losses, with a net income of -$100,515,000 and an EBITDA of -$107,913,000 over the same period. The company has a cash balance of $152.81M but also carries debt worth $34.76M. Profit margins are negative at -151.1%, while operating margin is 26.2%. Returns on equity and assets stand at -51.7% and -24.5%, respectively. Valuation metrics for Tango Therapeutics include a forward P/E ratio of -6.88, price to book of 6.21, and price to sales of 18.04. The company's revenue growth over the past year was substantial at 363.6%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.20B
- P/E Ratio
- N/A
- 52-Week High
- $11.20
- 52-Week Low
- $1.03
- Avg Volume
- 3.27M
- Beta
- 1.75
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 155